News

Friday June 5, 2026

AMR Bio Contributes to US National Action Plan on Combating Antibiotic-Resistant Bacteri...

Wednesday June 3, 2026

FDA Confirmation of Full Regulatory Transfer

Thursday May 28, 2026

AMR Bio Advances XF-73 Towards Phase 3 Development

Thursday May 21, 2026

AMR Bio launches with Phase 3-ready antimicrobial targeting surgical infections

Tuesday March 3, 2026

AMR Bio Presents Phase 2b Clinical Data at the 10th AMR Conference in Basel

Wednesday August 28, 2024

FDA Grants QIDP Designation to XF-73 Dermal Gel for Burn Wound Infections

Monday August 5, 2024

XF‐73 treatment of MRSA burn wound infection prevents bacterial invasion of the bloods...

Monday July 22, 2024

XF-73 Nasal gel significantly reduces post-surgical antibiotic use in cardiac surgery pa...